Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

[Risk of infection through use of selective immunomodulating drugs for rheumatoid arthritis].

Harboe E, Damås JK, Omdal R, Frøland SS, Sjursen H.

Tidsskr Nor Laegeforen. 2012 Sep 4;132(16):1867-71. doi: 10.4045/tidsskr.12.0180. Review. Norwegian.

2.
3.

Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.

Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.

Ann Rheum Dis. 2011 Oct;70(10):1719-25. doi: 10.1136/ard.2010.148783. Epub 2011 Jun 29.

PMID:
21719446
4.

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.

Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group..

J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15.

PMID:
21498482
5.

Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.

van Dartel SA, Fransen J, Kievit W, Dutmer EA, Brus HL, Houtman NM, van de Laar MA, van Riel PL.

Rheumatology (Oxford). 2013 Jun;52(6):1052-7. doi: 10.1093/rheumatology/kes413. Epub 2013 Jan 30.

PMID:
23365147
6.

Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.

Cobo-Ibáñez T, Descalzo MÁ, Loza-Santamaría E, Carmona L, Muñoz-Fernández S.

Rheumatol Int. 2014 Jul;34(7):953-61. doi: 10.1007/s00296-014-2945-y. Epub 2014 Jan 11.

PMID:
24414744
7.

Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data.

Keystone EC.

J Rheumatol. 2011 Aug;38(8):1552-62. doi: 10.3899/jrheum.100995. Epub 2011 May 15. Review.

PMID:
21572154
8.

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

Salliot C, Dougados M, Gossec L.

Ann Rheum Dis. 2009 Jan;68(1):25-32. doi: 10.1136/ard.2007.083188. Epub 2008 Jan 18. Review.

9.

[TNFalpha blockers and infectious risk in rheumatoid arthritis].

Raffeiner B, Botsios C, Ometto F, Bernardi L, Montante A, Sfriso P, Todesco S, Punzi L.

Reumatismo. 2009 Jul-Sep;61(3):165-73. Review. Italian.

10.

Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.

Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, Manesis EK, Archimandritis AI.

Ann Rheum Dis. 2010 Jul;69(7):1352-5. doi: 10.1136/ard.2009.127233. Epub 2010 May 14.

PMID:
20472596
11.
12.

Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.

Carroll MB, Bond MI.

Semin Arthritis Rheum. 2008 Dec;38(3):208-17. doi: 10.1016/j.semarthrit.2007.10.011. Epub 2008 Jan 25. Review.

PMID:
18221983
13.

Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis.

Ghrénassia E, Mékinian A, Rouaghe S, Ganne N, Fain O.

Joint Bone Spine. 2012 Jan;79(1):100-1. doi: 10.1016/j.jbspin.2011.07.003. Epub 2011 Sep 23. No abstract available.

PMID:
21944979
14.

The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.

Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S.

Int J Rheum Dis. 2009 Jul;12(2):118-24. doi: 10.1111/j.1756-185X.2009.01393.x.

PMID:
20374328
15.

Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.

Isaacs JD.

Expert Opin Biol Ther. 2009 Dec;9(12):1463-75. doi: 10.1517/14712590903379494. Review.

PMID:
19916731
16.
17.

[Rituximab and neutropenia].

Besada E.

Tidsskr Nor Laegeforen. 2012 Oct 30;132(20):2259; author reply 2259. doi: 10.4045/tidsskr.12.1147. Norwegian. No abstract available.

18.

Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.

Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.

Int J Rheum Dis. 2012 Jun;15(3):330-5. doi: 10.1111/j.1756-185X.2012.01715.x. Epub 2012 Feb 13.

PMID:
22709496
20.

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden.

Raaschou P, Simard JF, Holmqvist M, Askling J; ARTIS Study Group..

BMJ. 2013 Apr 8;346:f1939. doi: 10.1136/bmj.f1939.

Supplemental Content

Support Center